$LPTX
Leap Therapeutics Inc

2023 Q4 Form 10-Q Financial Statement

#000141057823002343 Filed on November 13, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.135M $3.330M
YoY Change 7.77% 4.52%
% of Gross Profit
Research & Development $11.69M $11.50M
YoY Change 5.9% -4.95%
% of Gross Profit
Depreciation & Amortization $4.000K $0.00
YoY Change 0.0% -100.0%
% of Gross Profit
Operating Expenses $14.82M $14.83M
YoY Change 6.29% -2.98%
Operating Profit -$14.83M
YoY Change -2.98%
Interest Expense $1.878M $580.0K
YoY Change 54.82% 5172.73%
% of Operating Profit
Other Income/Expense, Net $477.0K $550.0K
YoY Change -38.45% -15.64%
Pretax Income -$12.47M -$13.70M
YoY Change 4.27% -9.24%
Income Tax
% Of Pretax Income
Net Earnings -$12.47M -$13.70M
YoY Change 3.0% -9.26%
Net Earnings / Revenue
Basic Earnings Per Share -$0.51
Diluted Earnings Per Share -$0.46 -$0.51
COMMON SHARES
Basic Shares Outstanding 25.57M 25.57M
Diluted Shares Outstanding 26.99M

Balance Sheet

Concept 2023 Q4 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $70.64M $80.70M
YoY Change 7.85% 3.05%
Cash & Equivalents $70.64M $80.74M
Short-Term Investments
Other Short-Term Assets $183.0K $300.0K
YoY Change -47.86% -19.79%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $71.60M $81.76M
YoY Change 5.37% 2.28%
LONG-TERM ASSETS
Property, Plant & Equipment $5.000K $9.000K
YoY Change -75.0% -62.5%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $966.0K $900.0K
YoY Change 3120.0% 1900.0%
Total Long-Term Assets $1.228M $1.285M
YoY Change -48.9% -42.3%
TOTAL ASSETS
Total Short-Term Assets $71.60M $81.76M
Total Long-Term Assets $1.228M $1.285M
Total Assets $72.83M $83.05M
YoY Change 3.51% 1.07%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $6.465M $5.899M
YoY Change 14.28% -6.01%
Accrued Expenses $5.957M $4.770M
YoY Change 15.63% -5.39%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $12.68M $11.04M
YoY Change 13.0% -5.84%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00 $0.00
YoY Change -100.0% -100.0%
Total Long-Term Liabilities $0.00 $0.00
YoY Change -100.0% -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $12.68M $11.04M
Total Long-Term Liabilities $0.00 $0.00
Total Liabilities $12.68M $11.04M
YoY Change 10.42% -8.72%
SHAREHOLDERS EQUITY
Retained Earnings -$399.6M -$387.1M
YoY Change 25.59% 26.48%
Common Stock $26.00K $26.00K
YoY Change -73.74% -73.74%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $60.14M $72.01M
YoY Change
Total Liabilities & Shareholders Equity $72.83M $83.05M
YoY Change 3.51% 1.07%

Cashflow Statement

Concept 2023 Q4 2023 Q3
OPERATING ACTIVITIES
Net Income -$12.47M -$13.70M
YoY Change 3.0% -9.26%
Depreciation, Depletion And Amortization $4.000K $0.00
YoY Change 0.0% -100.0%
Cash From Operating Activities -$10.38M -$10.48M
YoY Change -20.24% -14.47%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities -$1.000K $0.00
YoY Change
Cash From Investing Activities -$1.000K $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 0.000
YoY Change
NET CHANGE
Cash From Operating Activities -10.38M -10.48M
Cash From Investing Activities -1.000K 0.000
Cash From Financing Activities 0.000 0.000
Net Change In Cash -10.38M -10.48M
YoY Change -20.24% -14.47%
FREE CASH FLOW
Cash From Operating Activities -$10.38M -$10.48M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001509745
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
25565414
CY2022 lptx Operating Lease Additional Liability
OperatingLeaseAdditionalLiability
609000
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
9902137
CY2023Q2 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.1
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-37990
dei Entity Registrant Name
EntityRegistrantName
LEAP THERAPEUTICS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
27-4412575
dei Entity Address Address Line1
EntityAddressAddressLine1
47 Thorndike St, Suite B1-1
dei Entity Address City Or Town
EntityAddressCityOrTown
Cambridge
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02141
dei City Area Code
CityAreaCode
617
dei Local Phone Number
LocalPhoneNumber
714-0360
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
dei Trading Symbol
TradingSymbol
LPTX
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
25565414
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
80743000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
65500000
CY2023Q3 lptx Research And Development Incentive Receivable Current
ResearchAndDevelopmentIncentiveReceivableCurrent
753000
CY2022Q4 lptx Research And Development Incentive Receivable Current
ResearchAndDevelopmentIncentiveReceivableCurrent
2099000
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
265000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
351000
CY2023Q3 us-gaap Assets Current
AssetsCurrent
81761000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
67950000
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
9000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
20000
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
363000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
669000
CY2022Q4 lptx Deferred Offering Costs Noncurrent
DeferredOfferingCostsNoncurrent
576000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
30000
CY2023Q3 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
913000
CY2022Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
1108000
CY2023Q3 us-gaap Assets
Assets
83046000
CY2022Q4 us-gaap Assets
Assets
70353000
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
5899000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
5657000
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4770000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5152000
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
369000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
416000
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
11038000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
11225000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
262000
CY2023Q3 us-gaap Liabilities
Liabilities
11038000
CY2022Q4 us-gaap Liabilities
Liabilities
11487000
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
240000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
240000000
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
25565414
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
9902137
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
26000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
10000
CY2023Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
458339000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
376896000
CY2023Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
760000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
128000
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-387117000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-318168000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
72008000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
58866000
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
83046000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
70353000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11503000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12102000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
61549000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
33931000
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3330000
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3186000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10672000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8889000
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
14833000
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
15288000
us-gaap Operating Expenses
OperatingExpenses
72221000
us-gaap Operating Expenses
OperatingExpenses
42820000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-14833000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-15288000
us-gaap Operating Income Loss
OperatingIncomeLoss
-72221000
us-gaap Operating Income Loss
OperatingIncomeLoss
-42820000
CY2023Q3 lptx Investment Income Interest Expense
InvestmentIncomeInterestExpense
1084000
CY2022Q3 lptx Investment Income Interest Expense
InvestmentIncomeInterestExpense
360000
lptx Investment Income Interest Expense
InvestmentIncomeInterestExpense
3089000
lptx Investment Income Interest Expense
InvestmentIncomeInterestExpense
404000
CY2022Q3 us-gaap Interest Expense
InterestExpense
11000
us-gaap Interest Expense
InterestExpense
49000
CY2023Q3 lptx Research And Development Incentive Income
ResearchAndDevelopmentIncentiveIncome
554000
CY2022Q3 lptx Research And Development Incentive Income
ResearchAndDevelopmentIncentiveIncome
652000
lptx Research And Development Incentive Income
ResearchAndDevelopmentIncentiveIncome
1124000
lptx Research And Development Incentive Income
ResearchAndDevelopmentIncentiveIncome
1276000
CY2023Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-501000
CY2022Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-807000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-953000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-1305000
lptx Change In Fair Value Of Warrant Liability
ChangeInFairValueOfWarrantLiability
12000
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-13696000
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-15094000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-68949000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-42494000
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.51
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.51
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.33
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.33
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.78
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.78
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.75
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.75
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
26987182
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
26987182
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11323909
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11323909
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
18240455
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
18240455
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11323909
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11323909
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-13696000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-15094000
us-gaap Net Income Loss
NetIncomeLoss
-68949000
us-gaap Net Income Loss
NetIncomeLoss
-42494000
CY2023Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
346000
CY2022Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
596000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
632000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
957000
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-13350000
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-14498000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-68317000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-41537000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
83318000
CY2022Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
596000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1253000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-15094000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
70073000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
107887000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
957000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3723000
us-gaap Net Income Loss
NetIncomeLoss
-42494000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
70073000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
84057000
CY2023Q3 lptx Fractional Value Paid In Cash
FractionalValuePaidInCash
1000
CY2023Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
346000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1300000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-13696000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
72008000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
58866000
us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
9805000
us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
13000
lptx Adjustments To Additional Paid In Capital Redemption Of Warrants
AdjustmentsToAdditionalPaidInCapitalRedemptionOfWarrants
29000
lptx Conversion Of Temporary Equity Into Permanent Equity Value
ConversionOfTemporaryEquityIntoPermanentEquityValue
67716000
lptx Adjustments To Additional Paid In Capital Reclassification Of Warrants To Equity
AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsToEquity
78000
lptx Fractional Value Paid In Cash
FractionalValuePaidInCash
1000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
632000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3875000
us-gaap Net Income Loss
NetIncomeLoss
-68949000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
72008000
us-gaap Profit Loss
ProfitLoss
-68949000
us-gaap Profit Loss
ProfitLoss
-42494000
lptx In Process Research And Development Costs Acquired In Connection With Acquisition Of Flame
InProcessResearchAndDevelopmentCostsAcquiredInConnectionWithAcquisitionOfFlame
29582000
us-gaap Depreciation
Depreciation
11000
us-gaap Depreciation
Depreciation
12000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
306000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
302000
us-gaap Share Based Compensation
ShareBasedCompensation
3875000
us-gaap Share Based Compensation
ShareBasedCompensation
3723000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-953000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-1305000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-83000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-382000
lptx Increase Decrease In Research And Development Incentive Receivable
IncreaseDecreaseInResearchAndDevelopmentIncentiveReceivable
-1279000
lptx Increase Decrease In Research And Development Incentive Receivable
IncreaseDecreaseInResearchAndDevelopmentIncentiveReceivable
212000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-1006000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
2167000
lptx Increase Decrease In Lease Liabilities
IncreaseDecreaseInLeaseLiabilities
-308000
lptx Increase Decrease In Lease Liabilities
IncreaseDecreaseInLeaseLiabilities
-303000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-801000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
912000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-33373000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-36030000
us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
50362000
us-gaap Payments To Acquire Businesses Gross
PaymentsToAcquireBusinessesGross
1393000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
48969000
us-gaap Payments For Repurchase Of Warrants
PaymentsForRepurchaseOfWarrants
29000
lptx Payment Of Fractional Shares
PaymentOfFractionalShares
1000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
210000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-30000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-210000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-323000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-368000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
15243000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-36608000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
65500000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
114916000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
80743000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
78308000
lptx Issuance Of Temporary Equity In Connection With Acquisition
IssuanceOfTemporaryEquityInConnectionWithAcquisition
67715000
lptx Reclassification Of Warrants From Liability To Equity
ReclassificationOfWarrantsFromLiabilityToEquity
78000
lptx Issuance Of Common Stock In Connection With Acquisition
IssuanceOfCommonStockInConnectionWithAcquisition
9805000
lptx Issuance Of Warrants For Purchase Of Common Stock In Connection With Acquisition
IssuanceOfWarrantsForPurchaseOfCommonStockInConnectionWithAcquisition
13000
us-gaap Liabilities Assumed1
LiabilitiesAssumed1
928000
lptx Remeasurement Of Right Of Use Asset And Lease Liability
RemeasurementOfRightOfUseAssetAndLeaseLiability
609000
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
80743000
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-387117000
us-gaap Net Income Loss
NetIncomeLoss
-68949000
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
80743000
CY2023Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2436000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2526000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The presentation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p>
lptx Australian Research And Development Incentive Percent Expenses Reimbursed
AustralianResearchAndDevelopmentIncentivePercentExpensesReimbursed
0.435
CY2022 lptx Australian Research And Development Incentive Percent Expenses Reimbursed
AustralianResearchAndDevelopmentIncentivePercentExpensesReimbursed
0.435
CY2023Q3 lptx Research And Development Incentive Receivable Current And Noncurrent
ResearchAndDevelopmentIncentiveReceivableCurrentAndNoncurrent
753000
CY2022Q4 lptx Research And Development Incentive Receivable Current And Noncurrent
ResearchAndDevelopmentIncentiveReceivableCurrentAndNoncurrent
2099000
CY2023Q3 lptx Research And Development Incentive Income
ResearchAndDevelopmentIncentiveIncome
554000
CY2022Q3 lptx Research And Development Incentive Income
ResearchAndDevelopmentIncentiveIncome
652000
lptx Research And Development Incentive Income
ResearchAndDevelopmentIncentiveIncome
1124000
lptx Research And Development Incentive Income
ResearchAndDevelopmentIncentiveIncome
1276000
CY2021Q4 lptx Research And Development Incentive Receivable
ResearchAndDevelopmentIncentiveReceivable
1189000
CY2022 lptx Research And Development Incentive Income
ResearchAndDevelopmentIncentiveIncome
2051000
CY2022 lptx Cash Received For Research And Development Incentive
CashReceivedForResearchAndDevelopmentIncentive
1064000
CY2022 lptx Research And Development Incentive Foreign Currency Translation Gain Loss
ResearchAndDevelopmentIncentiveForeignCurrencyTranslationGainLoss
-77000
CY2022Q4 lptx Research And Development Incentive Receivable
ResearchAndDevelopmentIncentiveReceivable
2099000
lptx Research And Development Incentive Income
ResearchAndDevelopmentIncentiveIncome
1124000
lptx Cash Received For Research And Development Incentive
CashReceivedForResearchAndDevelopmentIncentive
2333000
lptx Research And Development Incentive Foreign Currency Translation Gain Loss
ResearchAndDevelopmentIncentiveForeignCurrencyTranslationGainLoss
-137000
CY2023Q3 lptx Research And Development Incentive Receivable
ResearchAndDevelopmentIncentiveReceivable
753000
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Concentration of Credit Risk</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Financial instruments that potentially subject the Company to credit risk consist principally of cash and cash equivalents. All cash and cash equivalents are held in United States or Australian financial institutions and money market funds. At times, the Company may maintain cash balances in excess of the federally insured amount of $250 per depositor, per insured bank, for each account ownership category. Although the Company currently believes that the financial institutions with whom it does business will be able to fulfill their commitments to the Company, there is no assurance that those institutions will be able to continue to do so. The Company has not experienced any credit losses associated with its balances in such accounts for the year ended December 31, 2022 or for the nine months ended September 30, 2023.</p>
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4770000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5152000
CY2023Q3 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
49609000
CY2023Q3 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
49609000
CY2022Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
62074000
CY2022Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
62074000
CY2023Q3 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
49609000
CY2022Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
62074000
CY2023Q3 us-gaap Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
0.08
CY2022 lptx Operating Lease Additional Right Of Use Asset
OperatingLeaseAdditionalRightOfUseAsset
609000
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
363000
CY2023Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
369000
CY2023Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
113000
CY2023Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
6.78
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
12000
CY2023Q3 lptx Accrued Clinical Trials Current
AccruedClinicalTrialsCurrent
2134000
CY2022Q4 lptx Accrued Clinical Trials Current
AccruedClinicalTrialsCurrent
2093000
CY2023Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
200000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
533000
CY2022Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
116000
us-gaap Operating Lease Expense
OperatingLeaseExpense
341000
us-gaap Operating Lease Expense
OperatingLeaseExpense
336000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
113000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
268000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
381000
CY2023Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
12000
CY2023Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
369000
CY2023Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
5008139
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
12000
lptx Number Of Vote On Common Shares
NumberOfVoteOnCommonShares
1
us-gaap Dividends Common Stock
DividendsCommonStock
0
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1191715
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
35.94
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y5M19D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2318500
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.70
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
84568
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
17.29
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3425647
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
13.90
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y8M26D
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1108400
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
34.72
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y9M18D
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
3425647
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
13.90
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P8Y8M26D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
2.09
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
11.07
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.9037
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.8270
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0405
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0306
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y5M23D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y5M23D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P10Y
CY2023Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
6607000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y3M21D
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-13696000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-15094000
us-gaap Net Income Loss
NetIncomeLoss
-68949000
us-gaap Net Income Loss
NetIncomeLoss
-42494000
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-13696000
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-13696000
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-15094000
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-15094000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-68949000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-68949000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-42494000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-42494000
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
26987182
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
26987182
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11323909
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11323909
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
18240455
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
18240455
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11323909
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11323909
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.51
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.51
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.33
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.33
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.78
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.78
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.75
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.75
lptx Weighted Average Number Of Shares Outstanding Common Shares Issuable Upon Exercise Of Certain Warrants
WeightedAverageNumberOfSharesOutstandingCommonSharesIssuableUponExerciseOfCertainWarrants
1421768
CY2022Q3 lptx Weighted Average Number Of Shares Outstanding Common Shares Issuable Upon Exercise Of Certain Warrants
WeightedAverageNumberOfSharesOutstandingCommonSharesIssuableUponExerciseOfCertainWarrants
1421768
lptx Weighted Average Number Of Shares Outstanding Common Shares Issuable Upon Exercise Of Certain Warrants
WeightedAverageNumberOfSharesOutstandingCommonSharesIssuableUponExerciseOfCertainWarrants
1421768
CY2023Q3 lptx Weighted Average Number Of Shares Outstanding Common Shares Issuable Upon Exercise Of Certain Warrants
WeightedAverageNumberOfSharesOutstandingCommonSharesIssuableUponExerciseOfCertainWarrants
1421768
CY2023Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7297018
CY2022Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5097398
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7297018
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5097398
CY2023Q3 us-gaap Significant Supply Commitment Remaining Minimum Amount Committed
SignificantSupplyCommitmentRemainingMinimumAmountCommitted
469000
CY2023Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2023Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2023Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2023Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001410578-23-002343-index-headers.html Edgar Link pending
0001410578-23-002343-index.html Edgar Link pending
0001410578-23-002343.txt Edgar Link pending
0001410578-23-002343-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
lptx-20230930.xsd Edgar Link pending
lptx-20230930x10q.htm Edgar Link pending
lptx-20230930xex31d1.htm Edgar Link pending
lptx-20230930xex32d1.htm Edgar Link pending
lptx-20230930xex3d1.htm Edgar Link pending
lptx-20230930xex3d2.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
lptx-20230930_def.xml Edgar Link unprocessable
lptx-20230930x10q_htm.xml Edgar Link completed
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
lptx-20230930_lab.xml Edgar Link unprocessable
lptx-20230930_cal.xml Edgar Link unprocessable
lptx-20230930_pre.xml Edgar Link unprocessable